Exelixis (EXEL) and Bristol-Myers Squibb (BMY) to Present Phase 1b Data on Cobimetinib + Vemurafenib + Atezolizumab in Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma Monday October 10th
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?